Alignment Between CDA Recommendations and pCPA Negotiation Outcomes: Exploring Factors Influencing Reimbursement Success

What happens when Canada’s HTA supports access, but pricing negotiations fall short? At #ISPORAnnual, Mackenzie Mills will present new research exploring the alignment between Canada's Drug Agency (CDA) recommendations and pan-Canadian Pharmaceutical Alliance (pCPA) negotiation outcomes. Analysing 355 matched projects, the study reveals that even drugs with positive value assessments can fail to secure agreements—often due to steep price cuts or restrictive reimbursement conditions. Don’t miss the Access and Affordability session:

📍 Session: Access and Affordability
‍📅 Date: Friday, 16 May 2025
⏰ Time: 8:00 – 9:00 AM
📊 Research Abstract: 5801

Slides from the session are available here.
‍
Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!

‍

‍

‍